Key Events This Week
27 Apr: Stock opens strong at Rs.273.70 (+4.23%)
28 Apr: New 52-week high and all-time high reached (Rs.280.2 / Rs.278.2)
29 Apr: Minor consolidation with slight declines
30 Apr: Strong rebound closes week at Rs.276.25 (+3.17%)
May 07
BSE+NSE Vol: 10.67 lacs
The next results date for Bliss GVS Pharma Ltd is scheduled for 12 May 2026....
Read full news article
27 Apr: Stock opens strong at Rs.273.70 (+4.23%)
28 Apr: New 52-week high and all-time high reached (Rs.280.2 / Rs.278.2)
29 Apr: Minor consolidation with slight declines
30 Apr: Strong rebound closes week at Rs.276.25 (+3.17%)

Bliss GVS Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read full news article
With a remarkable 122.33% gain over the past year, Bliss GVS Pharma Ltd surged to a fresh 52-week high of Rs 280.2 on 28 Apr 2026, outpacing the Sensex which declined by 3.62% during the same period. This milestone caps a sustained rally fuelled by strong technical momentum and a series of bullish signals across multiple timeframes.
Read full news article
20 Apr: Stock opens at Rs.253.40, down 1.92% amid flat Sensex
22 Apr: New 52-week high at Rs.272.95 and all-time high at Rs.271.65
23 Apr: Further 52-week and all-time highs at Rs.277.7 and Rs.277.45
24 Apr: Week closes at Rs.262.60, down 2.36% on the day

With a remarkable 120.83% gain over the past year, Bliss GVS Pharma Ltd surged to a fresh 52-week high of Rs 277.7 on 23 Apr 2026, showcasing a sustained momentum that outpaces the broader Sensex, which declined by 2.58% over the same period.
Read full news article
From a 52-week low of Rs 105.05 to a new peak of Rs 272.95, Bliss GVS Pharma Ltd has more than doubled in value over the past year, delivering a remarkable 119.3% return. This surge comes amid a backdrop of mixed market conditions, with the Sensex down 0.73% today but up nearly 7% over the last three weeks, highlighting the stock’s standout momentum in the Pharmaceuticals & Biotechnology sector.
Read full news articleBliss GVS Pharma Limited has informed the Exchange regarding 'Pursuant to the provisions of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the extract copies of newspaper advertisement clippings of unaudited financial results of the Company for the second quarter and half year ended September 30, 2019 published in The Economic Times & The Free Press Journal an English Daily and Maharashtra Times & Navshkati a Regional Daily, on November 13, 2019.
Bliss GVS Pharma Limited has informed the Exchange regarding 'Please find enclosed herewith the copy of the newspaper advertisement of notice of Board Meeting of the Company will be held on Monday, November 11, 2019 at the registered office of the Company, inter-alia, to consider and approve the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2019 published in The Economic Times an English Daily and Maharashtra Times a Regional Daily, on November 05, 2019.
Bliss GVS Pharma Limited has informed the Exchange regarding a press release dated October 07, 2019, titled "we enclose herewith Press Release announcing that Kremoint Pharma Private Limited, India, a 70% subsidiary of Bliss GVS Pharma Limited (BGPL) has received a compliant certification from the U.S. Food and Drug Administration (FDA) that was based on the inspection conducted at the Company s facility located at M.I.D.C, Ambernath (East), Thane-District.".
12 May 2026
Bliss GVS Pharma Ltd has declared 50% dividend, ex-date: 18 Feb 26
Bliss GVS Pharma Ltd has announced 1:10 stock split, ex-date: 11 Mar 08
Bliss GVS Pharma Ltd has announced 3:5 bonus issue, ex-date: 26 Sep 08
No Rights history available